Acrongenomics of Geneva and Molecular Vision, an Imperial College spin-out company based in London, say they have successfully demonstrated the capability of their BioLED Lab on a Chip technology to measure biomarkers with high sensitivity and at low cost.
The device uses Molecular Vision's patented, organic semiconductor technology in a high sensitivity, small size medical diagnostic device.
BioLED technology uses semiconductor films located on either side of a microfluidics chip. One film illuminates the chip, where appropriate, while the other film detects an output signal, which is fed to a display. The device used two forms of detection utilizing chemiluminescence and fluorescence to detect different markers of interest.
Acrongenomics & Molecular Vision believe that this technology is capable of further miniaturisation along with large scale, low cost manufacturing, which will bring forward disposable, Point Of Care diagnostics for a large range of biomarkers.
Molecular Vision recently signed a major development contract with Acrongenomics to jointly exploit and commercialise the technology.